See more : Bit Brother Limited (BETS) Income Statement Analysis – Financial Results
Complete financial analysis of IntelGenx Technologies Corp. (IGXT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of IntelGenx Technologies Corp., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- POET Technologies Inc. (PTK.V) Income Statement Analysis – Financial Results
- Mene Inc. (MENE.V) Income Statement Analysis – Financial Results
- Mercury General Corporation (MCY) Income Statement Analysis – Financial Results
- Groupe IRD SA (IRD.PA) Income Statement Analysis – Financial Results
- Weizmann Limited (WEIZMANIND.NS) Income Statement Analysis – Financial Results
IntelGenx Technologies Corp. (IGXT)
About IntelGenx Technologies Corp.
IntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine; INT0046/2018 for adult use; INT0007/2006, an oral film product for treatment of erectile dysfunction; INT0043/2015, an oral film containing montelukast for treatment of Alzheimer; INT0027/2011 to treat opioid addition; INT0010/2006 for treatment of neuropathic pain and nausea in cancer patients undergoing chemotherapy; INT0036/2013, an oral film product for schizophrenia or bipolar 1 disorder; and INT0048/2020 for animal health. It is also developing INT0039/2013, INT0040/2014, INT0052/2020, INT0053/2020, and INT0054/2020. The company has licensing, development, and supply agreement with Tilray, Inc.; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was founded in 2003 and is headquartered in Montreal, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.04M | 950.00K | 1.54M | 1.54M | 742.00K | 1.82M | 5.20M | 5.22M | 5.10M | 1.66M | 948.00K | 1.21M | 440.00K | 1.34M | 1.28M | 976.61K | 835.42K | 265.90K | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 1.73M | 1.86M | 2.26M | 1.48M | 0.00 | 0.00 | 373.00K | 319.00K | 433.00K | 61.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -694.00K | -908.00K | -721.00K | 67.00K | 742.00K | 1.82M | 4.82M | 4.90M | 4.66M | 1.60M | 948.00K | 1.21M | 440.00K | 1.34M | 1.28M | 976.61K | 835.42K | 265.90K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | -66.79% | -95.58% | -46.97% | 4.34% | 100.00% | 100.00% | 92.82% | 93.89% | 91.50% | 96.32% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 3.43M | 3.03M | 2.72M | 2.64M | 3.77M | 5.10M | 2.62M | 1.77M | 1.03M | 1.08M | 561.00K | 1.72M | 1.34M | 1.57M | 1.42M | 2.09M | 603.40K | 510.41K | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.65M | 1.51M | 2.73M | 1.38M | 1.46M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 4.76M | 4.70M | 3.75M | 4.44M | 5.80M | 5.00M | 3.97M | 3.61M | 2.07M | 2.29M | 1.95M | 1.65M | 1.51M | 2.73M | 1.38M | 1.46M | 919.62K | 488.60K | 9.91K | 7.55K | 108.00 |
| Other Expenses | 0.00 | 777.00K | 791.00K | 734.00K | 718.00K | 719.00K | 735.00K | 511.00K | 171.00K | 74.00K | 72.00K | 46.00K | 37.00K | 44.00K | -237.90K | -376.84K | -132.37K | 33.91K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 8.18M | 8.51M | 7.26M | 7.81M | 10.29M | 10.82M | 7.32M | 5.88M | 3.28M | 3.44M | 2.59M | 3.41M | 2.89M | 4.34M | 2.57M | 3.17M | 1.57M | 1.03M | 9.91K | 7.55K | 108.00 |
| Cost & Expenses | 10.68M | 10.36M | 9.52M | 7.81M | 10.29M | 10.82M | 7.69M | 6.20M | 3.71M | 3.44M | 2.59M | 3.41M | 2.89M | 4.34M | 2.57M | 3.17M | 1.57M | 1.03M | 9.91K | 7.55K | 108.00 |
| Interest Income | 41.00K | 4.00K | 152.00K | 422.00K | 97.00K | 11.00K | 11.00K | 4.00K | 28.00K | 34.00K | 0.00 | 10.00K | 0.00 | 0.00 | 0.00 | 30.86K | 27.36K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.63M | 1.28M | 1.49M | 1.20M | 1.21M | 1.12M | 569.00K | 203.00K | 123.00K | 0.00 | 0.00 | 3.00K | 3.00K | 98.00K | 784.40K | 766.14K | 349.11K | 54.72K | 1.22K | 297.00 | 0.00 |
| Depreciation & Amortization | 766.00K | 777.00K | 791.00K | 734.00K | 718.00K | 719.00K | 735.00K | 511.00K | 171.00K | 74.00K | 72.00K | 46.00K | 37.00K | 44.00K | 44.60K | 51.77K | 42.01K | 33.91K | 0.00 | 0.00 | 0.00 |
| EBITDA | -7.69M | -8.64M | -7.04M | -5.11M | -8.74M | -8.28M | -1.76M | -470.00K | 1.59M | -1.71M | -1.57M | -2.22M | -2.60M | -3.14M | -1.24M | -2.45M | -948.17K | -731.53K | -146.53K | -7.55K | -108.00 |
| EBITDA Ratio | -739.65% | -908.63% | -458.57% | -330.83% | -1,177.22% | -453.29% | -33.63% | -8.93% | 31.11% | -102.83% | -165.30% | -178.81% | -547.50% | -221.24% | -97.11% | -219.13% | -68.71% | -290.98% | 0.00% | 0.00% | 0.00% |
| Operating Income | -9.49M | -9.41M | -7.98M | -6.26M | -9.55M | -9.00M | -2.49M | -981.00K | 1.39M | -1.78M | -1.64M | -2.21M | -2.45M | -3.00M | -1.29M | -2.19M | -729.62K | -767.02K | -9.91K | -7.55K | -108.00 |
| Operating Income Ratio | -913.47% | -990.84% | -520.00% | -405.70% | -1,287.06% | -493.31% | -47.99% | -18.79% | 27.20% | -107.29% | -172.89% | -182.62% | -555.91% | -224.53% | -100.60% | -224.43% | -87.34% | -288.46% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -436.00K | -1.28M | -1.34M | -780.00K | -1.11M | -1.11M | -558.00K | -199.00K | -95.00K | 34.00K | 0.00 | 10.00K | 172.00K | -558.00K | -686.70K | -306.67K | -196.81K | -14.12K | 35.29K | 0.00 | 0.00 |
| Income Before Tax | -9.93M | -10.69M | -9.32M | -7.04M | -10.66M | -10.11M | -3.05M | -1.18M | 1.29M | -1.75M | -1.64M | -2.25M | -2.45M | -3.10M | -2.07M | -2.96M | -1.16M | -781.14K | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | -955.44% | -1,125.26% | -607.04% | -456.22% | -1,436.66% | -554.17% | -58.73% | -22.61% | 25.34% | -105.24% | -172.89% | -186.26% | -557.27% | -231.56% | -161.94% | -302.88% | -139.44% | -293.77% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 1.28M | -6.00K | 1.20M | 1.21M | 11.00K | 11.00K | 4.00K | 28.00K | 0.00 | 0.00 | 3.00K | 3.00K | 98.00K | -130.30K | -151.58K | -64.08K | 14.12K | 11.12K | 7.84K | 108.00 |
| Net Income | -9.93M | -11.97M | -9.31M | -8.25M | -11.87M | -10.11M | -3.05M | -1.18M | 1.29M | -1.75M | -1.64M | -2.25M | -2.45M | -3.10M | -1.94M | -2.81M | -1.10M | -781.14K | -11.12K | -7.84K | -108.00 |
| Net Income Ratio | -955.44% | -1,259.68% | -606.64% | -534.07% | -1,599.33% | -554.17% | -58.73% | -22.61% | 25.34% | -105.24% | -172.89% | -186.26% | -557.27% | -231.56% | -151.75% | -287.36% | -131.77% | -293.77% | 0.00% | 0.00% | 0.00% |
| EPS | -0.06 | -0.07 | -0.07 | -0.08 | -0.13 | -0.14 | -0.05 | -0.02 | 0.01 | -0.03 | -0.03 | -0.05 | -0.06 | -0.09 | -0.08 | -0.14 | -0.07 | -0.05 | 0.00 | -0.01 | 0.00 |
| EPS Diluted | -0.06 | -0.07 | -0.07 | -0.08 | -0.13 | -0.14 | -0.05 | -0.02 | 0.01 | -0.03 | -0.03 | -0.05 | -0.06 | -0.09 | -0.08 | -0.14 | -0.07 | -0.05 | 0.00 | -0.01 | 0.00 |
| Weighted Avg Shares Out | 174.65M | 164.75M | 137.00M | 108.44M | 93.53M | 74.12M | 66.15M | 63.96M | 63.52M | 63.18M | 54.02M | 49.64M | 43.74M | 35.33M | 24.53M | 19.66M | 16.04M | 14.34M | 10.99M | 1.50M | 1.50M |
| Weighted Avg Shares Out (Dil) | 174.65M | 164.75M | 137.00M | 108.44M | 93.53M | 74.12M | 66.15M | 63.96M | 70.86M | 63.18M | 54.02M | 49.64M | 43.74M | 35.33M | 24.53M | 19.66M | 16.04M | 14.34M | 10.99M | 1.50M | 1.50M |
IntelGenx Announces Issuance of Shares in Payment of Interest on Outstanding Debentures
SAINT-LAURENT, Quebec, Dec. 08, 2020 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSXV: IGX) (OTCQB: IGXT) (the “Company” or “IntelGenx”) announces that it intends to issue 899,940 common shares of the Corporation (the “Common Shares”) at a deemed price of CAD...
IntelGenx Grants Stock Options
SAINT-LAURENT, Quebec, Nov. 23, 2020 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. ("IntelGenx", or the “Company”) (TSX-V: IGX) (OTCQB:IGXT) announced today that the Company's board of directors granted stock options to acquire a total of 1,365,000 common shares under the 2016...
IntelGenx Technologies Corp. (IGXT) CEO Horst Zerbe on Q3 2020 Results - Earnings Call Transcript
IntelGenx Technologies Corp. (IGXT) CEO Horst Zerbe on Q3 2020 Results - Earnings Call Transcript
IntelGenx Announces Issuance of U.S. Patent for Novel Technology Applicable to Cannabis-Containing Oral Films
SAINT LAURENT, Quebec, Nov. 11, 2020 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V:IGX) (OTCQB:IGXT) (“IntelGenx”), a leading oral drug delivery company, today announced that the United States Patent and Trademark Office has issued U.S. Patent 10,828,254, entitled “Oral film formulation for...
IntelGenx Announces Publication of a Study Evaluating Montelukast's Effect on Neurological Aging
- Data Suggest Montelukast May Inhibit Mental Decline , Higher Doses Optimal for Clinical Trials Assessing Impact on Neurological Disease -
IntelGenx to Report Third Quarter 2020 Financial Results on November 12, 2020 – Conference Call to Follow
SAINT LAURENT, Quebec, Nov. 05, 2020 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V:IGX) (OTCQB:IGXT) (“IntelGenx”) today announced that it will release its third quarter 2020 financial results after market close on Thursday, November 12, 2020.
IntelGenx Signs Letter of Intent with Heritage Cannabis for Long-Term Cannabis Filmstrip Supply Agreement
SAINT LAURENT, Quebec, Oct. 29, 2020 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX V:IGX)(OTCQB:IGXT) (the "Company" or "IntelGenx") today announced that it has executed a binding letter of intent (“LOI”) with Heritage Cannabis Holdings Corp. (“Heritage”), an international medical cannabis licensed producer...
Source: https://incomestatements.info
Category: Stock Reports